Outcome

Hyperbaric Oxygen Therapy (HBOT) significantly improved the skin condition of children with severe atopic dermatitis after a 30-day treatment as measured by the SCORAD and oSCORAD scales. Reductions in skin lesions redness swelling oozing/crusting scratch marks and skin lichenification were observed. Patients also reported less itching and better sleep quality. A notable decrease in serum total IgE concentration was found indicating a reduced allergic response.

Introduction

Atopic dermatitis (AD) particularly in its severe form is a chronic condition marked by an overactive immune response that results in significant skin inflammation and discomfort. Children suffering from severe AD often experience persistent skin lesions redness swelling and severe itching which can adversely impact their quality of life. Conventional treatments sometimes fail to provide adequate relief for these symptoms necessitating the exploration of alternative therapeutic options. Hyperbaric Oxygen Therapy (HBOT) has emerged as a potential intervention due to its known anti-inflammatory and tissue-healing properties. This study evaluates the impact of HBOT on children with severe AD by assessing clinical improvements in skin condition immune response and patient-reported outcomes after a 30-day treatment regimen. Findings from this investigation suggest that HBOT not only improves skin health but also enhances overall quality of life providing a promising new avenue for managing severe atopic dermatitis in pediatric patients.

Results

The study reports significant beneficial effects of hyperbaric oxygen therapy (HBOT) on children with severe atopic dermatitis (AD). Fifteen children underwent 30 daily HBOT sessions at a pressure of 2.5 ATA. The clinical improvements were meticulously assessed using the SCORAD and objective SCORAD (oSCORAD) scales yielding substantial reductions in the extent and severity of skin lesions. Specifically notable reductions were observed in skin lesions redness swelling oozing/crusting scratch marks and skin thickening.

Patient-reported outcomes also supported the efficacy of HBOT with participants experiencing less itching and improved sleep quality. These enhancements in overall well-being further emphasize the therapy’s impact on quality of life. Additionally a statistically significant decrease in serum total IgE concentration was documented indicating a reduced allergic response among the subjects.

However the study found no significant changes in the serum concentrations of cytokines such as IL-4 IL-6 and IL-10 nor in specific immune cell populations including CD4+CD25highCD127−FOXP3+ Treg and NKT lymphocytes. This suggests that while HBOT markedly improves clinical symptoms and quality of life its effects on certain immunological parameters remain limited.

In summary the study elucidates the selective but potent benefits of HBOT for children with severe atopic dermatitis highlighting significant improvements in skin condition and overall quality of life alongside a reduction in serum total IgE levels. These findings establish a strong foundation for the therapeutic potential of HBOT in managing severe atopic dermatitis in pediatric patients.

Conclusion

In conclusion this study underscores the promising potential of hyperbaric oxygen therapy (HBOT) as a treatment for children with severe atopic dermatitis (AD). The 30-day HBOT regimen led to substantial improvements in the skin condition of the participants as evidenced by significant reductions in skin lesions redness swelling oozing/crusting scratch marks and skin thickening measured through the SCORAD and oSCORAD scales. Additionally there was a notable alleviation of itching and enhancements in sleep quality which collectively contribute to an improved quality of life. The marked decrease in serum total IgE concentration further suggests a reduced allergic response post-therapy. Although there were no significant changes in certain immune cells and cytokine levels the overall findings highlight HBOT’s targeted efficacy in mitigating severe AD symptoms. These encouraging results warrant further research to elucidate the mechanisms underlying HBOT’s effects and explore its broader application in pediatric dermatology.